Dr. Eiko T. Browning, MD

Dr. Browning practices at Rocky Mountain Cancer Centers in Thornton, Colorado.

Dr. Browning's NPI, 1215083811, was assigned on January 26, 2007. Dr. Browning graduated from University Of Michigan Medical School in 2006. Dr. Browning holds Colorado license 48220.

Dr. Browning's primary practice is Rocky Mountain Cancer Centers, at 8820 Huron St, Thornton, CO 80260 in Adams County. The practice phone is (303) 930-7800.

Dr. Browning's primary practice is Rocky Mountain Cancer Centers in Thornton, Colorado. Dr. Browning is also affiliated with HCA HealthONE Mountain Ridge. The medical group on file is Rocky Mountain Cancer Centers. Dmand AI also links Dr. Browning to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Browning practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Browning's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Browning is board certified in hematology by the American Board of Internal Medicine. Dr. Browning is licensed in Colorado.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Browning treats.

CMS data shows 46,301 Medicare services from Dr. Browning across 54 procedure codes in 2024, for 438 Medicare patients. Medicare paid $724,779 for them.

CMS counts 438 Medicare patients who saw Dr. Browning in 2024. The largest group is 65 to 74, with 190 patients. 70% of them have high blood pressure, and 66% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Browning's median patient age at 71, with 64% women.

In 2024, Dr. Browning wrote 2,122 Medicare Part D claims for 398 patients. 83% of them were for generic drugs. CMS names the drug for 1,824 of them, across 37 drugs with 11 or more claims each, at $2,248,262 in total drug cost. In 2023, CMS named 1,554 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 73 out of 100 for Dr. Browning for performance year 2024, reported through an alternative payment model (APM). Dr. Browning accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Browning as offering telehealth.

Dmand AI links 2 papers to Dr. Browning in 2014. The most frequent topics are Adenocarcinoma and Lung Neoplasms. Dr. Browning's most frequent co-authors are David R. Camidge, MD, Willis Bon Barrow, MD and Douglas J. Kemme, MD.

CMS Open Payments shows 139 general payments to Dr. Browning from 50 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 91% of the total. Genentech, Inc. paid the most, $366.

Dr. Browning graduated from University Of Michigan Medical School in 2006.

Dr. Browning is in network with 16 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.